Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma

Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Resistance mechanisms to venetoclax in patients with progressive CLL

Multiple myeloma highlights and more from ASH 2018

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia

Myeloma XI study: Quadruplet regimen for transplant eligible patients

Developments in CAR T treatments for adult patients

Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy

ASH 2018: Expert overview of the latest in CLL, ALL and AML

Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients